|Severe thrombocytopenia related to trastuzumab infusion.|
|Jump to Full Text|
|PMID: 21709639 Owner: NLM Status: MEDLINE|
|BACKGROUND: Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein which causes uncontrolled proliferation of malignant breast cells.
CASE REPORT: We report a case of severe thrombocytopenia related to trastuzumab administration. Three days after the first dose of single-agent trastuzumab, the patient was admitted to the hospital with nose bleeding, petechiae and platelet counts of 5 × 10⁹/L.
CONCLUSIONS: The patient showed a self-limiting trastuzumab-related thrombocytopenia. Among the reported cases of trastuzumab-induced severe thrombocytopenia, this patient is the only one who did not interrupt trastuzumab treatment. It is possible that our patient showed progressive reduction of immune-mediated thrombocytopenia caused by trastuzumab administration.
|Marina Mantzourani; Helen Gogas; Aikaterini Katsandris; John Meletis|
Related Documents :
|3232099 - To certify or not to certify: clinical social work decisions and involuntary hospitaliz...
11229259 - Crossed aphasia leading to pure word deafness.
23091329 - A case report on 30-week premature twin babies with congenital myotonic dystrophy conce...
14513329 - Ectopic thyroid in the gallbladder: report of a case.
12114789 - Dyshormonogenetic goiter: a clinicopathologic study of 56 cases.
6894289 - Dissolution of gallstones following thyroxine administration. a case report.
3772709 - Factors involved in chylothorax following repair of congenital posterolateral diaphragm...
8692719 - A case of myospherulosis occurring in the perirenal adipose tissue.
25183229 - Immediate autotransplantation of third molars: an experience of 57 cases.
|Type: Case Reports; Journal Article|
|Title: Medical science monitor : international medical journal of experimental and clinical research Volume: 17 ISSN: 1643-3750 ISO Abbreviation: Med. Sci. Monit. Publication Date: 2011 Jul|
|Created Date: 2011-06-28 Completed Date: 2011-11-04 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 9609063 Medline TA: Med Sci Monit Country: Poland|
|Languages: eng Pagination: CS85-7 Citation Subset: IM|
|1st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens, Greece.|
|APA/MLA Format Download EndNote Download BibTex|
administration & dosage,
Antibodies, Monoclonal, Humanized
Breast Neoplasms / drug therapy*
Carcinoma, Ductal, Breast / drug therapy*
Immunoglobulins, Intravenous / therapeutic use
Receptor, erbB-2 / metabolism*
Thrombocytopenia / chemically induced*, drug therapy
|0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Immunoglobulins, Intravenous; EC 126.96.36.199/ERBB2 protein, human; EC 188.8.131.52/Receptor, erbB-2; P188ANX8CK/trastuzumab|
Journal ID (nlm-ta): Med Sci Monit
Journal ID (iso-abbrev): Med. Sci. Monit
Publisher: International Scientific Literature, Inc.
© Med Sci Monit, 2011
Received Day: 07 Month: 1 Year: 2011
Accepted Day: 02 Month: 2 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 01 Month: 7 Year: 2011
Volume: 17 Issue: 7
First Page: CS85 Last Page: CS87
PubMed Id: 21709639
Publisher Id: 881838
|Severe thrombocytopenia related to trastuzumab infusion|
|1st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens, Greece
|Correspondence: John Meletis, 1st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, 17 Agiou Thoma, Goudi, Athens 11527, Greece, e-mail: firstname.lastname@example.org
The HER receptors are proteins that are embedded into the cell membrane and communicate molecular signals regulating gene functions. They also regulate cell growth, survival, adhesion, migration and differentiation functions that are amplified or silenced in cancer cells. Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein. When binding to defective HER2 proteins, the HER2 protein no longer causes uncontrolled proliferation of malignant breast cells, and thus the drug increases the survival of women with breast cancer.
Trastuzumab is approved by the US FDA for the treatment of early- and late- stage HERB2-positive breast cancer, as it provides survival advantage in both metastatic and adjuvant disease [1,2]. The most common reported adverse-effects include a flu-like syndrome, hypersensitivity reaction and nausea; the most serious adverse effect is cardiac dysfunction. We report a patient with breast cancer and severe thrombocytopenia that was related by trastuzumab therapy .
A 56-year-old woman presented at our oncology department with a 3-month history of a mass in her right breast. One month later the patient had a resection of the right breast mass and the biopsy showed ductal carcinoma of the breast, grade II, negative for estrogen and progesterone receptors but positive for HER2 (3+ positivity). The patient had 11 lymph nodes removed from the right axilla and none of them had a positive biopsy for metastasis.
Adjuvant therapy with trastuzumab was started at a loading dose of 8 mg/kg. Her full blood laboratory examination was normal. Three days after trastuzumab initiation, she noticed a petechiae rash covering her whole body and nose bleeding started the same day. She went to the hospital, where a severe thrombocytopenia (platelets counts of 5×109/l) was revealed. The patient was admitted for the management of thrombocytopenia. She was treated for immune thrombocytopenic purpura and received therapy with intravenous immunoglobulin (IVIGs) 0.5 g/kg for 5 days with good response. Her symptoms and platelets counts recovered to within normal range on the fifth day of treatment and the patient was released.
The patient was admitted in our department for continuation of her treatment with trastuzumab and daily blood examination. After 21 days after the first cycle, a second cycle of trastuzumab at dose of 6 mg/kg was administered. Three days later, her platelets had dropped to 28×109/l. Disseminated intravascular coagulation was excluded based on normal levels of fibrinogen, fibrin degradation products and the cross-linked fragment, D-dimer. She was negative for human immunodeficiency virus and serological testing did not reveal other viral infections (HBV, HCV, CMV, EBV, Parvovirus B19, Herpes zoster virus, Herpes virus 1 and 2). Bone marrow aspirate and trephine biopsy showed no abnormalities, with normal megakaryopoiesis and no infiltration by tumor cells. Additional laboratory tests provided no evidence of secondary thrombocytopenia, suggesting a diagnosis of ITP, according to the American Society of Hematology criteria. The platelet counts very soon recovered (50×109/l on the 6th day), and 10 days later their number was within normal limits. During the third cycle of trastuzumab, the platelet counts dropped to 128×109/l on the third day after trastuzumab infusion, and then the patient continued and completed the treatment with trastuzumab without thrombocytopenia and without any other adverse event.
Several medications are implicated to drug-induced thrombocytopenia, but the diagnosis is usually made by exclusion . In our case, treatment with trastuzumab led to severe thrombocytopenia and the same phenomenon reoccurred twice, but stopped after the third cycle of treatment. Although there are reports in the literature of 3 patients who had thrombocytopenia after treatment with trastuzumab, none of them could continue on trastuzumab therapy [4–7]. The exact pathogenesis of drug-induced thrombocytopenia is unknown. However, there are several models that try to explain this phenomenon and implicate hapten-induced antibodies, drug-dependent antibodies, glycoprotein IIb/IIIa inhibitors or direct bone marrow toxicity [3,8]. In our patient, the time of onset of thrombocytopenia is directly connected with the infusion of trastuzumab and could be attributed to classic drug-induced immune-mediated thrombocytopenia. Management of drug-induced thrombocytopenia includes immunoglobulin therapy, or corticosteroids and platelets transfusion in cases of severe hemorrhage. Our patient had a course of IVIGs at the first episode of thrombocytopenia and continued on trastuzumab treatment without other problems.
In conclusion, our patient showed a self-limiting trastuzumab-related thrombocytopenia. There are 3 other cases reported in the literature of trastuzumab-induced severe thrombocytopenia, but this patient is the only one who did not interrupt trastuzumab treatment. We do not know why our patient showed progressive reduction of this possible immune-mediated thrombocytopenia that was caused by trastuzumab.
The authors declare that they have no competing interests.
Written consent was obtained from the patient for publication of this case report.
fn10-medscimonit-17-7-cs85Source of support: Departmental sources
|1.||Ménard S,Pupa SM,Campiglio M,et al. Biologic and therapeutic role of HER2 in cancerOncogeneYear: 20032265707814528282|
|2.||Hudis CA. Trastuzumab-mechanism of action and use in clinical practiceN Engl J MedYear: 2007357395117611206|
|3.||Warkentin TE. Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosisN Engl J MedYear: 20073568919317329695|
|4.||Jara Sánchez C,Olier Gárate C,García-Donas Jiménez J,et al. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable diseaseAnn OncolYear: 2009201607819633054|
|5.||Cathomas R,von Moos R. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinibAnn OncolYear: 2009201606819622591|
|6.||Drudi F,Gianni L,Fantini M,et al. Trastuzumab-related thrombocytopenia: always a self-limiting complication?Ann OncolYear: 2010216686920032121|
|7.||Parikh O,Neave F,Palmieri C. Severe thrombocytopenia induced by a single infusion of trastuzumabClin Breast CancerYear: 200882858618650161|
|8.||Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesisSemen HematolYear: 19993626|
Keywords: thrombocytopenia, trastuzumab.
Previous Document: Association between Takayasu arteritis and ulcerative colitis - case report and review of serologica...
Next Document: Serpiginous-like choroiditis as sign of intraocular tuberculosis.